United States - English - NLM (National Library of Medicine)

medical purchasin solutions, llc - vasopressin, unspecified (unii: y87y826h08) (vasopressin, unspecified - unii:y87y826h08) - vasostrict ® is indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines. vasostrict ® is contraindicated in patients with known allergy or hypersensitivity to 8-l-arginine vasopressin or chlorobutanol. pregnancy category c risk summary: there are no adequate or well-controlled studies of vasostrict ® in pregnant women. it is not known whether vasopressin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. animal reproduction studies have not been conducted with vasopressin [see clinical pharmacology (12.3)]. clinical considerations: because of increased clearance of vasopressin in the second and third trimester, the dose of vasostrict ® may need to be up-titrated to doses exceeding 0.1 units/minute in post-cardiotomy shock and 0.07 units/minute in septic

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - vasopressin, unspecified (unii: y87y826h08) (vasopressin, unspecified - unii:y87y826h08) - vasostrict® is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. vasostrict® 10 ml multiple dose vial is contraindicated in patients with known allergy or hypersensitivity to 8‑l-arginine vasopressin or chlorobutanol. the 1 ml single dose vial, 50 ml and 100 ml pre-mixed single dose vial does not contain chlorobutanol and is therefore contraindicated only in patients with a known allergy or hypersensitivity to 8-l-arginine vasopressin. risk summary there are no available data on vasostrict® use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.  animal reproduction studies have not been conducted with vasopressin. clinical considerations dose adjustments during pregnancy and the postpartum period: because of increased clearance of vasopressin in the second and third trimester, the dose of vasostrict® may need to be increased [see dosage and administration (2.2) and clinical pharmacology (12.3)] . maternal adverse reactions: vasostrict® may produce tonic uterine contractions that could threaten the continuation of pregnancy. there are no data on the presence of vasopressin injection in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. safety and effectiveness of vasostrict® in pediatric patients with vasodilatory shock have not been established. clinical studies of vasopressin did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy [see warnings and precautions (5), adverse reactions (6), and clinical pharmacology (12.3)] .

United States - English - NLM (National Library of Medicine)

medical purchasing solutions, llc - vasopressin, unspecified (unii: y87y826h08) (vasopressin, unspecified - unii:y87y826h08) - vasostrict ® is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. vasostrict ® 10 ml multiple dose vial is contraindicated in patients with known allergy or hypersensitivity to 8‑l-arginine vasopressin or chlorobutanol.  the 1 ml single dose vial does not contain chlorobutanol and is therefore contraindicated only in patients with a known allergy or hypersensitivity to 8-l-arginine vasopressin. risk summary there are no available data on vasostrict ® use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted. clinical considerations dose adjustments during pregnancy and the postpartum period: because of increased clearance of vasopressin in the second and third trimester, the dose of vasostrict® may need to be increased [see dosage and

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - vasopressin, unspecified (unii: y87y826h08) (vasopressin, unspecified - unii:y87y826h08) - vasostrict® is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. vasostrict® 10 ml multiple dose vial is contraindicated in patients with known allergy or hypersensitivity to 8‑l-arginine vasopressin or chlorobutanol.  the 1 ml single dose vial does not contain chlorobutanol and is therefore contraindicated only in patients with a known allergy or hypersensitivity to 8-l-arginine vasopressin. risk summary there are no available data on vasostrict® use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.  animal reproduction studies have not been conducted with vasopressin. clinical considerations dose adjustments during pregnancy and the postpartum period: because of increased clearance of vasopressin in the second and third trimester, the dose of vasostrict® may need to be increased [see dosage and administration (2.2) and clinical pharmacology (12.3)] .

United States - English - NLM (National Library of Medicine)

ciba vision - naphazoline hydrochloride (unii: mz1131787d) (naphazoline - unii:h231gf11bv) - solution - 1 mg in 1 ml - vaso con regular is indicated for use as a topical ocular vasoconstrictor. contraindicated in the presence of an anatomically narrow angle or in narrow angle glaucoma or in persons who have shown hypersensitivity to any component of this preparation.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - ramipril - oral tablet - ramipril anti-hypertensive active 1.25 mg/tb - cardiovascular system - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - congestive heart failure | hypertension | dilated cardiomyopathy | elevated systolic blood pressu | mitral and/or tricuspid regur | valvular insufficiency

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - ramipril - oral tablet - ramipril anti-hypertensive active 5.0 mg/tb - cardiovascular system - dog | bitch | castrate | puppy - congestive heart failure | dilated cardiomyopathy | mitral and/or tricuspid regur | valvular insufficiency

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - ramipril - oral tablet - ramipril anti-hypertensive active 2.5 mg/tb - cardiovascular system - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - congestive heart failure | hypertension | dilated cardiomyopathy | elevated systolic blood pressu | mitral and/or tricuspid regur | valvular insufficiency

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - ramipril - oral tablet - ramipril anti-hypertensive active 5.0 mg/tb - cardiovascular system - dog | bitch | castrate | puppy - congestive heart failure | dilated cardiomyopathy | mitral and/or tricuspid regur | valvular insufficiency

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - ramipril - oral tablet - ramipril anti-hypertensive active 2.5 mg/tb - cardiovascular system - dog | bitch | castrate | puppy - congestive heart failure | dilated cardiomyopathy | mitral and/or tricuspid regur | valvular insufficiency